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This study was aimed to identify the expression and the correlation of insulin-like growth factor-1 (IGF-1) system and their prognostic
impacts in cervical cancer. Seventy-two patients with early-stage cervical cancer were eligible. We obtained the serum levels of total
IGF-1 and IGF binding protein-3 (IGFBP-3) by enzyme-linked immunosorbent assay and the expression of IGF-1 receptor (IGF-1R) in
cancerous tissue by immuno-fluorescent (IF) stains. The 5-year recurrence-free and overall survival rates were significantly lower
(P¼0.003 and P¼0.01, respectively) among patients with high-grade expression of tissue IGF-1R, compared with those with
low-grade expression. After adjustment for other factors, preoperative serum total IGF-1 or IGFBP-3 levels failed to predict cancer
death and recurrence. High-grade expression of IGF-1R and elevated preoperative squamous cell carcinoma antigen level were
independent predictors of both death and recurrence, and combination of both factors could further help identify the subgroup of
patients at higher death risk. The IF staining indicates the colocalisation of IGF-1 and IGF-1R in the cancerous tissues, whereas the
IGF-1R expression is not correlated with circulating levels of IGF-1 or IGFBP-3. In early-stage cervical cancer, IGF-1 system may have a
paracrine or autocrine function and the adverse impacts on prognosis by IGF-1R overexpression are implicated.
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Cancer of the cervix is the second most common cancer among
women worldwide (Schoell et al, 1999). An estimated 500000
cases are newly diagnosed and nearly 200000 deaths are
attributable to the disease in the world annually. A growing body
of evidence has accumulated to indicate that oncogenic types of
human papillomavirus (HPV) serve as an important factor in the
development of the precursors of cervical cancer (zur Hausen,
1991; Syrja ¨nen et al, 1992; Mun ˜oz et al, 2003). The protein
products of HPV DNA appear to be interactive with the
antioncogenic function of the retinoblastoma gene and the p53
gene. However, only a small fraction of those infected by HPV
develop cancer, indicating that other factors contribute to the
progression to cervical cancer. Despite intensive investigation, the
tumour biology of this disease is still largely unknown. Although
prognostic factors such as pelvic lymph node metastasis affects
the outcome of cervical cancer, the variability in progression-free
and overall survival (OS) among patients with similar clinical
and pathological characteristics makes it difficult to predict the
outcome reliably.
The insulin-like growth factor 1 (IGF-1) system is comprised of
ligand (IGF-1), receptor (IGF-1R) and a family of binding proteins
(IGF-BPs). The insulin-like growth factor 1 is a 7.6kDa polypep-
tide secreted in the liver and is also synthesized widely in other
tissues (Jones and Clemmons, 1995). In addition to endocrine
function, potential paracrine and autocrine functions are also
revealed in IGF-responsive tissues, such as epiphyseal growth
plate, ovary and uterus. Insulin-like growth factor binding protein
3 (IGFBP-3), a 29–48kDa protein that localises outside the cell
surface, is the major serum carrier of IGF to IGF-1R. Most actions
of IGF-1 are mediated through IGF-1R signalling, resulting in
mitogenic and metabolic functions in vivo as well as in vitro
(Yu and Rohan, 2000). The binding of IGF-1R is suppressed by
IGFBPs, especially IGFBP-3, producing an inhibitory effect on
cell growth. There is a controversy over the complex feature of
IGF-1 system in carcinogenesis. In a systemic review, high serum
IGF-1 levels were associated with increased risk of prostate and
premenopausal breast cancer, but not with increased risk of lung
cancer or colorectal cancer (Renehan et al, 2004). As to IGFBP-3,
high concentrations were only correlated to increased risk of
premenopausal breast cancer. On the other hand, one study
showed that IGFBP-3 may have a protective effect in ovarian
cancer (Dal Maso et al, 2004).
Earlier we have investigated the regulatory mechanism of
IGF-1R signalling and its importance in cervical cancer formation
by cell lines and animal model (Shen et al, 2006). The growth and
invasiveness of cervical cancer cells were dose-dependently
stimulated by IGF-1, whereas those of normal cervical epithelial
cells were not. The treatment of blocking antibody of IGF-1R
remarkably decreased IGF-1R phosphorylation and downstream
activation of Akt and Erk1/2, hereby inhibiting tumour growth and
causing tumour regression in SCID mice model. Little information
is available on the clinical implication of IGF-1 system in cervical
cancer except for a small clinical study showing higher serum level
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sof IGF-1 in women with squamous intraepithelial lesion than
normal control (Wu et al, 2003). This study aims to investigate the
association of IGF-1 system and clinical outcome of cervical
cancer, by analysing the serum levels of IGF-1 and IGFBP-3, and
tissue abundances of IGF-1R for the same patient. The results
suggest the important function of IGF-1 system in predicting the
clinical outcome of patients with early-stage cervical cancer.
MATERIALS AND METHODS
Patient population
Patients were identified through the Gynaecology Service database
at National Cheng Kung University Hospital, Taiwan, between
January 2000 and November 2002. They have been followed up
regularly, and the date of latest record retrieved was December 31,
2007. We included patients with early-stage carcinoma of uterine
cervix who experienced radical or modified radical hysterectomy
and pelvic lymphadenectomy. The staging met the criteria of the
clinical staging of International Federation of Gynaecology and
Obstetrics (FIGO). The histological classification was defined
according to the World Health Organization classification. The
cervical tumour volume of surgical specimen was calculated using
the formula: p/6 (R1 R2 R3) (Chou et al, 1994). Preoperative
serum levels of tumour markers were available. Initially, 263
patients of newly diagnosed cervical cancer between 2000 and 2002
were recruited into our study. However, patients who had minimal
residual tumours, who had experienced hysterectomy elsewhere
or who received primary therapy instead of surgery were excluded:
40 had undergone conization, 28 with stage IA disease, 11 were
referred for postoperative treatment, and 75 preferred irradiation
or concurrent chemoradiation as the primary therapeutic moda-
lity. Besides, informed consents were not available in another 37
patients. Finally, 72 participants were enroled for this study and
for final analysis. The research protocol and consent form were
approved by the institutional review board. We reviewed the
medical records and pathological slides, which provided clinical
characteristics, pathological diagnosis, treatment and outcome
information.
Clinical definitions
Both OS and recurrence-free survival (RFS) were calculated from
the date of diagnosis. The duration of OS was measured to the date
of death from any cause; survivors were censored on the date they
were last known to be alive. The duration of RFS was designated to
the first clinical recurrence or death from any cause, unless the
patient was recurrence-free at the time of last contact, in which
case it was measured to the date of last contact. The preoperative
body mass index (BMI) was calculated using the universal
formula: the weight/the square of the height (kg/m
2).
Levels of total IGF-I and IGFBP-3 in preoperative serum
A non-extraction IGF-1 enzyme-linked immunosorbent assay
(ELISA) kit (DSL-10-2800) and IGFBP-3 ELISA kit (DSL-10-6600)
from Diagnostics Systems Laboratories, Inc., Webster, TX, USA
was used for the determination of preoperative serum IGF-1 and
IGFBP-3 levels. Samples were tested in duplicates and repeated if
the correlation coefficient between the absorbance and the amount
in the standards was less than 0.95.
Immunofluorescent stains of cervical cancer tissue
samples
Those surgical specimens were processed for immunofluorescent
(IF) stains using monoclonal antibodies against IGF-1 (clone M23,
Catalogue Number CBL52, Chemicon International, Temecula, CA,
USA) or IGF-1R (clone 24–31, Catalogue Number MAB1120,
Chemicon International). The monoclonal antibody against
IGF-1R recognises the a-subunit of IGF-1R with the epitope
between amino acid 283–440 (exon 4–6) of IGF-1R and shows no
cross-reaction with insulin receptor (Schumacher et al, 1993; Yu
and Yoko, 2007). We used Alexa 488-labeled or Alexa 594-labeled
secondary antibodies (Molecular Probes, OR) and Hoechst 33258
(Sigma-Aldrich, Dorset, UK) for immunofluorescence. The IF
stains were calculated manually using a CoolSnap-Pro colour
digital camera (Roper Scientific, Trenton, NJ, USA) in 15–20 high-
power fields. The intensity and distribution of IF stains of IGF-1R
were graded using a scale of 1–4 in each specimen. Grade 1
indicates that IGF-1R staining intensity and distribution are less
than 25% of tumour area. Grade 2 indicates that the staining
intensity and distribution are more than 25%, but less than 50% of
tumour area. Grade 3 indicates that the staining intensity and
distribution are more than 50%, but less than 75% of tumour area.
Grade 4 indicates that the staining intensity and distribution are
more than 75% of tumour area. Human placenta was used as the
positive control for IGF-1R and IGF-1. A negative control, for
which the primary antibody was substituted with the same
concentration of the appropriate immunoglobulin G, was used in
each staining run. Sections of each patient’s specimen were
examined for histology, intensity and distribution of IF stains of
IGF-1 and IGF-1R by two trained investigators who were blinded
to each patient’s clinical history.
Statistics
Data were analysed by SPSS (version 13.0; SPSS Inc, Chicago, IL,
USA). The possible prognostic factors included age (451 vs p51),
FIGO stage (XIIA, IB2 vs pIB1), cell type (adenocarcinoma,
others vs squamous cell carcinoma), tumour volume (411.38 vs
p11.38cm
3), preoperative squamous cell carcinoma antigen (SCC
Ag) level (42.5 vs p2.5ngml
 1), carcinoembryonic antigen
(CEA) level (43.5 vs p3.5ngml
 1), parametrial invasion (yes vs
no), pelvic lymph node metastases (yes vs no), BMI (425 vs p25),
adjuvant therapy (radiotherapy (RT) alone, chemotherapy (CT)
alone, RTþCT vs no), tissue IGF-IR overexpression (high vs low),
serum total IGF-1 level (p125.11 vs 4125.11ngml
 1) and serum
IGFBP-3 level (p3499.82 vs 43499.82ngml
 1). The cutoff points
were mainly chosen based on Receiver Operating Curve analysis.
Survival data were assessed by Kaplan–Meier method. Univariate
analysis by the log-rank test evaluates the possible influence on
survival or disease recurrence covariates. Multivariate Cox
proportional hazards model by stepwise methods was performed
to test the independent function of each screened prognostic
variables of univariate analysis. Student’s t-test for continuous
variables was used to test the difference between two subgroups
of serum IGF-1 or IGFBP-3 levels, which were categorized by
the other categorical variables. The correlation between serum
IGF-1/IGFBP-3 and other continuous parameters was analysed
with linear regression model. All P-values presented are two-sided
and considered as statistically significant when Pp0.05.
RESULTS
Patterns of intratumour IGF-1 and IGF-1R expression in
cervical cancer
We at first examined the expression level of IGF-1R in surgical
specimens of early-stage cervical cancer by IF staining. As shown
in Figure 1Aa, IGF-1R protein was scanty in normal or
noncancerous cervical tissues of all surgical specimens examined
(n¼72). In contrast, cervical cancer tissues clearly expressed
IGF-1R protein with different amounts (Figure 1Ab). In addition,
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sthe double stainings of IGF-1R and IGF-1 indicate the colocalisa-
tion of IGF-1 and IGF-1R in the cancerous tissues (Figure 1B).
Clinicopathological characteristics and clinical outcome
The patient characteristics were shown in Table 1. We first analyse
the patient characteristics to identify the possible predictors by the
univariate analysis (Table 1). Of the 10 covariates, 7 were related to
increased relative risk of death and disease recurrence, including
FIGO staging, tumour size, preoperative SCC Ag and CEA levels,
parametrial invasion, lymph node metastasis and adjuvant
therapy. These seven potential prognostic factors were included
subsequently in multivariate analysis with IGF-1 system.
The correlation between serum IGF-1/IGFBP-3 and other
prognostic factors
Further, we analysed the relationship between serum IGF-1/IGFBP-3
and other variables. By linear regression model, we found IGF-1
levels may be related to preoperative CEA levels and tumour
volumes with marginal statistical significance (P¼0.07 and
P¼0.08, respectively). In addition, there may be certain association
between IGFBP-3 and lymph node metastasis (P¼0.05), and BMI
(P¼0.06).
IGF-1 system and clinical outcome
Univariate association between IGF-1 system and clinical out-
come We grouped the patients by IGF-1R grades, serum levels of
IGF-1 or IGFBP-3 and analysed the clinical outcome accordingly
(Table 2). The patients were further categorized as low-grade
(grade 1–2) and high-grade IGF-1R expressions (grade 3–4)
(Figure 1Ab) because of the limited case numbers in each category.
Of the 72 patients with cervical cancer assessed, 17 deaths and 17
recurrences were encountered. In the univariate analysis, the tissue
expression level of IGF-1R is a significant predictor of death as well
as disease recurrence. The 5-year RFS and OS rates were 96.9 and
90.6% among patients with low-grade overexpression of tissue
IGF-1R, whereas RFS and OS were 54.6 and 59.9% among those
with high-grade overexpression (Figure 2). The serum level of
IGF-1 is a significant predictor of survival (relative risk, 4.17 (95%
CI: 1.20–14.55)), but not disease recurrence. However, the
circulating level of IGFBP-3 is not associated with risk of survival
and disease recurrence.
Multivariate association between IGF-1 system and clinical
outcome By multivariate Cox regression analysis, high-grade
overexpression of IGF-1R alone and elevated preoperative SCC Ag
level alone were both independent predictors of death and
recurrence (Table 3). Assuming proportional hazards, more than
80% power was estimated when testing the hypothesis of increased
risk in OS and RFS among those with high-grade expression of
IGF-1R relative to that among those with low-grade expression.
Elevated preoperative CEA level and stage XIIA were of significant
predictive value of death and recurrence, respectively. After
adjustment for other factors, preoperative serum total IGF-1 or
IGFBP-3 levels failed to predict cancer death and recurrence. By
two-covariate prognostication, combination of increased SCC Ag
level and high-grade IGF-1R overexpression or combination of
elevated CEA level and lower IGF-1 level were remarkably related
to advancing death risk. The 5-year OS were illustrated in Figure 3.
Moreover, the serum level of IGF-1 or IGFBP-3 did not statistically
differ between the two distinct IGF-1R overexpressions (P¼0.77
and P¼0.07, respectively), indicating no direct correlation
IGF-IR+nucleus
Noncancerous tissue a
A
B
b Cervical carcinoma
Cervical carcinoma
IGF-IR+nucleus IGF-IR+nucleus Low grade High grade
Squamous epithelia
Stroma
IGF-I IGF-IR Merge
Figure 1 (A) Pattern of IGF-1R expression in the surgical specimens of cervical cancer. (a) IGF-1R protein was scanty in normal or noncancerous cervical
tissues of all surgical specimens examined (n¼72). (b) Adjacent cervical cancerous tissues clearly expressed IGF-1R protein with different abundances.
Representative pictures for cervical cancer samples with different IGF-1R grades. Low grade indicates that the distribution of IGF-1R staining is less than 50%
of tumour area, whereas high grade indicates that the distribution of IGF-1R staining is more than 50% of tumour area. The double-staining technique was
used to identify IGF-1R (red) and nucleus (blue) in cervical cancer tissue. Nuclei were stained with Hoechst 33258. Scale bar, 30mm. (B) Colocalisation of
IGF-1 and IGF-1R in cervical cancer tissues. The double-staining technique was used to identify IGF (green) and IGF-1R (red) in cervical cancer tissues. A
representative picture of samples of cervical cancer. Scale bar, 40mm.
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sbetween circulating IGF-1 or IGFBP-3, and IGF-1R overexpression
in cervical cancer cells.
DISCUSSION
This study is a retrospective analysis of patients with early-stage
cervical cancer who received surgery as their primary treatment.
We provide evidence that IGF-1 system has a certain function in
tumour formation and clinical outcome of cervical cancer. This
conclusion is supported by the following findings: (i) high-grade
overexpression of IGF-1R is an independent predictor of cervical
cancer death and recurrence, and when combined with elevated
serum SCC Ag level could further help identify the subgroup of
patients at higher death risk. (ii) Preoperative serum total IGF-1 or
IGFBP-3 levels failed to predict cervical cancer death and
recurrence. (iii) The colocalisation of IGF-1 and IGF-1R in the
cancerous tissues, and the lack of correlation between circulating
IGF-1 or IGFBP-3, and IGF-1R overexpression in cervical cancer
cells suggest likely autocrine or paracrine IGF-1 stimulation of
IGF-1R signalling.
IGF-1R has been believed to be pivotal in tumorigenesis.
Defective IGF-1R has been shown to inhibit cellular transformation
and tumorigenesis (Prager et al, 1994). Complexity in IGF
signalling pathways has not been well established in cervical
cancer. Steller et al described that overexpression of IGF-1R in
cervical cancer cell lines and explants controlled the proliferation
of cancer cells (Steller et al, 1996). We have pointed out that IGF-1,
as a stimulator through IGF-1R signalling, interacted with avb3
integrin in cervical cancer cell invasiveness and proliferation
(Shen et al, 2006). Further, we recognised that IGF-1 stimulated
potassium-chloride cotransporters, which were required for
invasion and proliferation of cervical cancer, ovarian cancer and
breast cancer cells (Shen et al, 2004; Hsu et al, 2007). Related
Table 1 Patient characteristics and univariate analysis for relative risk of death and disease recurrence of clinicopathological factors
Characteristics n % RR of death P RR of recurrence P
Age Median, 51
Range, 31–77
p51 37 51.4 1 1
451 35 48.6 0.97 0.95 0.92 0.86
FIGO stage
pIB1 56 77.8 1 1
IB2 10 13.9 2.05 0.28 2.70 0.14
XIIA 6 8.3 8.37 o0.001 14.44 o0.001
Cell type
Squamous cell carcinoma 53 73.6 1 1
Adenocarcinoma 15 20.8 1.13 0.84 0.69 0.56
Others 4 5.6 o0.001 0.98 o0.001 0.98
Tumor volume (cm
3) Median, 6.65
Range, 0–82.47
p11.38 45 62.5 1 1
411.38 27 37.5 7.21 0.001 11.05 o0.001
Preoperative SCC Ag (ngml
 1) Median, 1.40
Range, 0–62.3
p2.5 48 66.7 1 1
42.5 24 33.3 6.23 0.001 4.83 0.002
Preoperative CEA (ngml
 1) Median, 1.10
Range, 0–13.7
p3.5 62 86.1 1 1
43.5 10 13.9 3.92 0.007 3.65 0.01
BMI Median, 24.76
Range, 16.30–33.12
p25 38 52.8 1 1
425 31 43.1 0.77 0.60 1.50 0.42
Parametrial involvement
No 52 72.2 1 1
Yes 20 27.8 3.27 0.02 3.11 0.02
Lymph node metastases
No 55 76.4 1 1
Yes 17 23.6 3.36 0.01 4.37 0.003
Adjuvant therapy
No 21 29.2 1 1
RT alone 19 26.4 2.32 0.33 2.45 0.30
CT alone 16 22.2 1.45 0.71 0.68 0.76
RT+CT 16 22.2 7.56 0.01 10.66 0.002
BMI¼body mass index; CEA¼carcinoembryonic antigen; CT¼Chemotherapy; FIGO¼Federation of Gynecology and Obstetrics; RR¼relative risk; RT¼Radiotherapy;
SCC Ag¼squamous cell carcinoma antigen.
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spathways on the synthesis, expression, ligand-receptor interaction
and tyrosine-kinase activation of IGF-1R in cervical cancer deserve
further clarifications.
The function of IGF-1R expression in disease outcome in
cervical cancer has rarely been discussed in earlier literature. Our
present study reported the significantly adverse impacts on RFS
and OS in patients with high-grade IGF-1R overexpression.
Therefore, the application of IGF-1R overexpression may be
rational to predict clinical prognosis in operable cervical cancer.
A reliable serum biomarker to predict occurrence, progression
or prognosis of human cancers can offer early diagnosis or
surveillance of therapy efficacy. Scientists have contributed to
investigating the correlation of serum IGF-1 or IGFBP-3 to the
prevalence of a variety of cancers, but have given diverse results.
Table 2 Univariate analysis for relative risk of death and disease recurrence of IGF-1 system
Variable n % RR of death P RR of recurrence P
IGF-1R expression
1 22 30.6 — —
2 10 13.8 — —
3 28 38.9 — —
4 12 16.7 — —
Low-grade (grade 1–2) 32 44.4 1 1
High-grade (grade 3–4) 40 55.6 4.31 0.02 15.95 0.007
Serum total IGF-1 (ngml
 1) Median, 119.22
Range, 9.11–330.21
4125.11 31 43.1 1 1
p125.11 41 56.9 4.17 0.03 2.00 0.20
Serum IGF-BP3 (ngml
 1) Median, 3322.91
Range, 1564.00–6529.00
43499.82 28 38.9 1 1
p3499.82 44 61.1 1.63 0.36 1.26 0.65
IGF-BP3¼IGF binding protein-3; IGF-1¼insulin-like growth factor-1; IGF-1R¼IGF-1 receptor; RR¼relative risk.
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Figure 2 Kaplan–Meier estimates of overall survival and recurrence-free survival by IGF-1R overexpression in cervical cancer specimens. (A) Five-year
overall survival rates are 90.6 and 59.9% in patients with low-grade and high-grade IGF-1R overexpression, respectively (P¼0.01). (B) Five-year recurrence-
free survival rates are 96.9 and 54.6% in patients with low-grade and high-grade IGF-1R overexpression, respectively (P¼0.003).
Table 3 Multivariate analysis for relative risk of death and disease recurrence of prognostic factors by the Cox proportional hazard model
Variable RR of death 95% CI P
Preoperative SCC Ag (42.5 vs p2.5ngml
 1) 3.49 1.11–10.99 0.03
Preoperative CEA (43.5 vs p3.5ngml
 1) 3.01 1.09–8.31 0.03
IGF-1R expression (high vs low) 5.66 1.26–25.47 0.02
Serum total IGF-1 level (p125.11vs 4125.11ngml
 1) 2.90 0.76–11.13 0.12
RR of recurrence 95% CI P
FIGO stage (XIIA vs pIB1) 7.61 2.37–22.78 0.001
Preoperative SCC Ag (42.5 vs p2.5ngml
 1) 4.39 1.45–13.26 0.009
IGF-1R expression (high vs low) 10.06 1.25–81.30 0.03
Serum total IGF-1 level (p125.11vs 4125.11ngml
 1) 1.30 0.40–4.23 0.67
CEA¼carcinoembryonic antigen; CI¼confidence interval; FIGO¼Federation of Gynecology and Obstetrics; IGF-1¼insulin-like growth factor-1; IGF-1R¼IGF-1 receptor;
RR¼relative risk; SCC Ag¼squamous cell carcinoma antigen.
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prostate cancer (Chan et al, 1998), lung cancer (Yu et al, 1999),
colorectal cancer (Ma et al, 1999), premenopausal breast cancer
(Toniolo et al, 2000) and younger aged ovarian cancer (Peeters
et al, 2007). However, in a systemic review (Renehan et al, 2004),
the correlation was not significant in lung cancer and colorectal
cancer after adjustment. As to IGFBP-3, higher serum IGFBP-3
levels to the increased risk of premenopausal breast cancer
(Renehan et al, 2004) and distant recurrence of postmenopausal
and estrogen receptor-positive breast cancer (Goodwin et al, 2002)
were observed. In contrast, elevated IGFBP-3 levels may have a
protective function in ovarian cancer occurrence (Dal Maso et al,
2004). As to cervical cancer, studies showed lower serum IGF-1
level correlated to increased risk of cervical cancer (Serrano et al,
2006) and its precancer lesions (Schaffer et al, 2007). One study
inferred that the IGFBP-3 level could be used in predicting
prognosis of cervical cancer (Mathur et al, 2003), but the study
result should be limited because of small sample size and
concealed stage. Our study illustrated that in early-stage cervical
cancer patients, lower IGF-1 level seemed to be associated with
worse OS but was not of an independent value, and there was no
relationship between IGFBP-3 and survival. It is still unclear why
increased serum IGF-1 level may have a sheltery effect on the risk
of cervical cancer, whereas the unfavourable effect of serum IGF-1
is addressed in certain sex hormone-related cancers, such as
prostate cancer or breast cancer. One of the theories is that the
natural history to cervical cancer may differ from sex hormone-
related cancers (Schaffer et al, 2007). Second, the different effects
may be generated by the differences between Asian and Caucasian
patients, related to socioeconomic and diet influences. In our
study, serum levels of IGF-1 and IGFBP-3 did not differ between
two subgroups of IGF-1R overexpression with colocalised IGF-1 in
the specimen sections. The possible hypothesis is that the IGF
system may contribute to the regional influences in the battlefield,
suggesting paracrine or autocrine function in agreement on prior
suppositions (Bergmann et al, 1995; Schips et al, 2004; Schillaci
et al, 2005). More candidates should be enroled in further studies
to realise the differences of serum levels of IGF-1 between normal
individuals, patients with precancer lesions and cervical cancer.
Pretreatment SCC Ag or CEA assays, as tumour-associated
antigens, have been identified to be valuable in distinguishing
high-risk patients requiring adjuvant therapy and in predicting
prognosis in early-stage cervical cancer (Bae et al, 1997; Takeda
et al, 2002; Reesink-Peters et al, 2005). In our cohorts, the
integration of SCC Ag level and IGF-1R overexpression or the
combination of CEA and IGF-1 levels could produce more accurate
estimates in identifying patient subgroups of poor prognosis.
On the basis of former results of IGF-1R expression of primary
site or possible circulating tumour cells in many cancers, targeting
therapy with IGF-1R antibody was enormously developed within
recent years (Bradley and Douglas, 2005; Gotlieb et al, 2006; de
Bono et al, 2007; Hartog et al, 2007; Imsumran et al, 2007).
Although many issues, such as the potential blockade of endocrine,
nervous and myocardial functions, or the application in conjuga-
tion with conventional chemotherapy, were raised, this new
strategy may bring new hope in cancer treatment.
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